Anther smorgasbord of word salad spun conspiracy t
Post# of 126531
(Total Views: 217)
Posted On: 01/26/2020 1:04:12 PM
Anther smorgasbord of word salad spun conspiracy theories, with a big old 'irony cherry' on top.
Seriously? 'SO a thinker would ask'.
You'd be surprised at how often I'll Google a key phrase from your posts...'this military test tube disease created by the Chinese in Canada,...'and I come up with jack.
Real science however? If the results of this trial are positive and the vaccine makes it to market, and there is no repeat of the 1918 pandemic, bummer huh? Oh well, there's always building 7.
Wednesday, April 3, 2019
NIH begins first-in-human trial of a universal influenza vaccine candidate
Investigational vaccine designed to provide broad, durable protection from flu.
Seriously? 'SO a thinker would ask'.
You'd be surprised at how often I'll Google a key phrase from your posts...'this military test tube disease created by the Chinese in Canada,...'and I come up with jack.
Real science however? If the results of this trial are positive and the vaccine makes it to market, and there is no repeat of the 1918 pandemic, bummer huh? Oh well, there's always building 7.
Wednesday, April 3, 2019
NIH begins first-in-human trial of a universal influenza vaccine candidate
Investigational vaccine designed to provide broad, durable protection from flu.
Quote:
This H1N1 candidate vaccine protected animals from infection of H5N1, a different influenza subtype, indicating that the antibodies induced by the vaccine can protect against other influenza subtypes within “group 1,” which includes both H1 and H5. In future clinical trials, the VRC plans to evaluate a vaccine that is designed to protect against “group 2” influenza subtypes, which include H3 and H7.
Initial data from an earlier VRC clinical trial evaluating a ferritin nanoparticle vaccine that included both hemagglutinin head and stem showed that the platform is safe and well-tolerated in humans. As with all clinical trials, a protocol safety review team will regularly assess study data to monitor safety of the participants in this Phase 1 study.
The VRC expects the clinical trial to complete enrollment by the end of 2019 and hopes to begin reporting results in early 2020. For more information about the trial, visit ClinicalTrials.gov and search identifier NCT03814720.
(0)
(0)